- Report
- May 2026
- 182 Pages
Global
From €3992EUR$4,500USD£3,415GBP
- Report
- April 2026
- 178 Pages
Global
From €4125EUR$4,650USD£3,529GBP
- Report
- August 2026
- 381 Pages
Global
From €5190EUR$5,850USD£4,439GBP
- Report
- November 2025
- 200 Pages
Global
From €7053EUR$7,950USD£6,033GBP
- Report
- November 2025
- 200 Pages
Global
From €7053EUR$7,950USD£6,033GBP
- Report
- August 2026
- 111 Pages
Global
From €4214EUR$4,750USD£3,605GBP
- Report
- August 2026
- 120 Pages
Global
From €4214EUR$4,750USD£3,605GBP
- Report
- April 2026
- 180 Pages
Global
From €4214EUR$4,750USD£3,605GBP
- Report
- May 2026
- 150 Pages
Global
From €2474EUR$2,789USD£2,116GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2474EUR$2,789USD£2,116GBP
- Report
- February 2026
- 160 Pages
Global
From €2945EUR$3,320USD£2,519GBP
€3682EUR$4,150USD£3,149GBP
- Report
- September 2025
- 140 Pages
Global
From €15965EUR$17,995USD£13,656GBP
- Report
- May 2026
- 152 Pages
Global
From €3504EUR$3,950USD£2,997GBP
- Report
- July 2026
- 160 Pages
Global
From €2945EUR$3,320USD£2,519GBP
€3682EUR$4,150USD£3,149GBP
- Report
- July 2026
- 160 Pages
Global
From €2945EUR$3,320USD£2,519GBP
€3682EUR$4,150USD£3,149GBP
- Report
- July 2026
- 160 Pages
Global
From €2945EUR$3,320USD£2,519GBP
€3682EUR$4,150USD£3,149GBP
- Report
- March 2026
- 118 Pages
Global
From €3500EUR$4,226USD£3,099GBP
- Report
- July 2026
- 68 Pages
Asia Pacific
From €4214EUR$4,750USD£3,605GBP
- Report
- January 2025
- 120 Pages
Global
From €5279EUR$5,950USD£4,515GBP
- Report
- August 2025
- 188 Pages
Global
From €3145EUR$3,545USD£2,690GBP
€3495EUR$3,939USD£2,989GBP

The antiarrhythmic market is a subset of the cardiovascular drug market, which includes drugs used to treat abnormal heart rhythms. Antiarrhythmic drugs are used to treat arrhythmias, which are abnormal heart rhythms that can cause symptoms such as palpitations, dizziness, and chest pain. These drugs work by blocking or slowing down electrical signals in the heart, restoring the normal rhythm. Common types of antiarrhythmic drugs include beta blockers, calcium channel blockers, and potassium channel blockers.
The antiarrhythmic market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, Sanofi, Novartis, and GlaxoSmithKline. Other companies in the market include Bristol-Myers Squibb, AstraZeneca, and Boehringer Ingelheim. Show Less Read more